Skip to Content
scroll

Telix Pharmaceuticals (TLX) $10.43

TLX +14.24%:  Delivered a materially better FY25 result than expected today and guided revenue higher for FY26. Topline growth is coming through which has allayed short-term earnings pressure.

FY25 Highlights

  • FY25 revenue $US803.8m, +56% y/y – consensus $US726m
  • Adjusted EBITDA $39.5m, -41% y/y – consensus $US36.9m
  • Net loss $7.1m (vs $33.7m profit y/y) – breakeven exp
  • Cash balance $141.9m
  • FY26 revenue guidance $950–970m – consensus was $US858m

Revenue momentum remains strong and guidance points to another year of solid top-line growth. The earnings pullback reflects deliberate reinvestment, higher amortisation post-acquisitions, and non-cash finance costs. With three pivotal trials underway and label expansions planned, 2026 is shaping up as a key year for TLX after a challenging 2025.

TLX
MM is cautiously bullish TLX ~$10
Add To Hit List
chart
image description
Telix (TLX)
image description

Relevant suggested news and content from the site

Back to top